Noble Romans (NROM) EBITDA Margin (2010 - 2026)

Noble Romans' EBITDA Margin history runs 16 years deep, the most recent figure standing at 14.1% for Q1 2026.

• On a quarterly basis, EBITDA Margin rose 76.0% year-over-year to 14.1% in Q1 2026; TTM through Mar 2026 was 14.78%, a 465.0% increase from a year earlier, with the FY2025 full-year figure at 14.61%, up 488.0% from the prior year.
• EBITDA Margin advanced to 14.1% in Q1 2026 per NROM's latest filing, from 3.81% in the prior quarter.
• Across five years, EBITDA Margin topped out at 46.13% in Q1 2023 and bottomed at 11.87% in Q4 2022.
• The 5-year median for EBITDA Margin is 13.34% (2025), against an average of 13.02%.
• Across the five-year window, EBITDA Margin slumped 3540065 bps in 2022 and soared 4153 bps in 2023, its largest moves.
• Year by year, EBITDA Margin stood at 11.87% in 2022, then jumped by 276 bps to 20.87% in 2023, then plunged by 91 bps to 1.85% in 2024, then soared by 107 bps to 3.81% in 2025, then soared by 270 bps to 14.1% in 2026.
• Per Business Quant, the three latest NROM EBITDA Margin figures stand at 14.1% (Q1 2026), 3.81% (Q4 2025), and 19.77% (Q3 2025).